

Bunge LTD
Form 4
March 04, 2014

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Teixeira Vicente

(Last) (First) (Middle)

C/O BUNGE LTD., 50 MAIN STREET, 6TH FLOOR

(Street)

WHITE PLAINS,, NY 10606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bunge LTD [BG]

3. Date of Earliest Transaction (Month/Day/Year)
02/28/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director ___ 10% Owner
X Officer (give title below) ___ Other (specify below)

Chief Personnel Officer

6. Individual or Joint/Group Filing(Check Applicable Line)
X Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount (A) or (D) Price		
Common Stock <u>(1)</u>	02/28/2014		A		3,780 A \$ 0	22,494	D
Common Stock <u>(2)</u>	02/28/2014		A		175 A \$ 0	22,669	D
Common Stock	03/03/2014		F		1,479 <u>(3)</u> D \$ 79.47	21,190	D
Common Stock <u>(4)</u>	03/03/2014		A		13 A \$ 78.43	21,203	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option (Right to Buy)	\$ 79.47	02/28/2014		A	18,750	<u>(5)</u> 02/27/2024	Common Stock	18,750

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Teixeira Vicente C/O BUNGE LTD., 50 MAIN STREET 6TH FLOOR WHITE PLAINS,, NY 10606			Chief Personnel Officer	

Signatures

/s/ John Tropeano,
Attorney-in-Fact

03/04/2014

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents common shares received on February 28, 2014, in settlement of performance-based restricted stock units ("PBRsUs") granted under the 2009 Bunge Limited Equity Incentive Plan.
 - (2) Represents common shares received on March 3, 2014, pursuant to a dividend reinvestment feature of the PBRsUs under the 2009 Bunge Limited Equity Incentive Plan.
 - (3) Withholding of common stock pursuant to the terms of the 2009 Bunge Limited Equity Incentive Plan for the purposes of the payment of tax liability incident to the vesting and settlement of PBRsUs.
 - (4)

Edgar Filing: Bunge LTD - Form 4

Represents restricted stock units acquired on March 3, 2014, pursuant to a dividend reinvestment feature under the 2009 Bunge Limited Equity Incentive Plan.

(5) This option is exercisable in three equal installments beginning on February 28, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. text-indent: 0px"> Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.4317

10 (partnership shares)

£13.4317

10 (matching shares)

d)

Aggregated information

Aggregated volume

Price

20 Ordinary Shares

£13.4317

e)

Date of the transaction

2018-03-09

f)

Place of the transaction

London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- | | |
|---------------------------------------|--|
| a) Name | Mr R G Connor |
| b) Position/status | President, Global Manufacturing & Supply |
| c) Initial notification/
amendment | Initial notification |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Explanation of Responses:

Edgar Filing: Bunge LTD - Form 4

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.
- c) Price(s) and volume(s)
 Price(s) Volume(s)
 £13.4317 10 (partnership shares)
 £13.4317 10 (matching shares)
- Aggregated information
- d) Aggregated volume 20 Ordinary Shares
 Price £13.4317
- e) Date of the transaction 2018-03-09
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 a) Name Mr S Dingemans
 b) Position/status Chief Financial Officer
 c) Initial notification/ amendment Initial notification
 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward

Explanation of Responses:

Edgar Filing: Bunge LTD - Form 4

Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£13.4317	10 (partnership shares)
	£13.4317	10 (matching shares)

Aggregated information

d) Aggregated volume	20 Ordinary Shares
Price	£13.4317
e) Date of the transaction	2018-03-09
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr N Hirons
b) Position/status	SVP, Global Ethics & Compliance
c) Initial notification/ amendment	Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
--	--

	ISIN: GB0009252882
--	--------------------

b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.
------------------------------	---

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£13.4317	10 (partnership shares)
	£13.4317	10 (matching shares)

Aggregated information

d) Aggregated volume	20 Ordinary Shares
Price	£13.4317
e) Date of the transaction	2018-03-09
f) Place of the transaction	London Stock Exchange (XLON)

Explanation of Responses:

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr L Miels
 - b) Position/status President, Global Pharmaceuticals
 - c) Initial notification/ amendment Initial notification
2. platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.
- c) Price(s) and volume(s)

Price(s)	Volume(s)
£13.4317	10 (partnership shares)
£13.4317	10 (matching shares)

Aggregated information

- d) Aggregated volume 20 Ordinary Shares
Price £13.4317
- e) Date of the transaction 2018-03-09
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr D S Redfern
 - b) Position/status Chief Strategy Officer
 - c) Initial notification/ amendment Initial notification
2. platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc

Explanation of Responses:

Edgar Filing: Bunge LTD - Form 4

- b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place
 3. where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c) Price(s) and volume(s)
 Price(s) Volume(s)
 £13.4317 10 (partnership shares)
 £13.4317 10 (matching shares)

Aggregated information

d) Aggregated volume 20 Ordinary Shares

Price £13.4317

e) Date of the transaction 2018-03-09

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas

b) Position/status SVP, Human Resources

c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

Explanation of Responses:

Edgar Filing: Bunge LTD - Form 4

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£13.4317	10 (partnership shares)
	£13.4317	10 (matching shares)

Aggregated information

d) Aggregated volume	20 Ordinary Shares
Price	£13.4317
e) Date of the transaction	2018-03-09
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr P C Thomson
b) Position/status	President, Global Affairs
c) Initial notification/ amendment	Initial notification

Details of the issuer, emission allowance market participant, auction

2. platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument	ISIN: GB0009252882
--	--------------------

b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.
------------------------------	---

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£13.4317	9 (partnership shares)
	£13.4317	9 (matching shares)

Aggregated information

d) Aggregated volume	18 Ordinary Shares
Price	£13.4317
e) Date of the transaction	2018-03-09
f) Place of the transaction	London Stock Exchange (XLON)

Explanation of Responses:

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Dr P J T Vallance
 - b) Position/status President, R&D
 - c) Initial notification/
amendment Initial notification
- Details of the issuer, emission allowance market participant, auction
2. platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
- Details of the transaction(s): section to be repeated for (i) each type of
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place
where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each
(‘Ordinary Shares’)
ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares
under the Company's Share
Reward Plan.

- c) Price(s) and volume(s)

Price(s)	Volume(s)
£13.4317	9 (partnership shares)
£13.4317	9 (matching shares)

Aggregated information

- d) Aggregated volume 18 Ordinary Shares
- Price £13.4317
- e) Date of the transaction 2018-03-09
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mrs V A Whyte
 - b) Position/status Company Secretary
 - c) Initial notification/
amendment Initial notification
- Details of the issuer, emission allowance market participant, auction
2. platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

Explanation of Responses:

Edgar Filing: Bunge LTD - Form 4

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £13.4317 10 (partnership shares) £13.4317 10 (matching shares)
Aggregated information	
d) Aggregated volume	20 Ordinary Shares
Price	£13.4317
e) Date of the transaction	2018-03-09
f) Place of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: March 12, 2018

By: VICTORIA WHYTE-----

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc